One biotech IPO is scheduled for the week ahead, and pipeline activity indicates that a few more may be on the way.
ORIC Pharmaceuticals (ORIC), a Phase 1 biotech developing small molecule therapies for treatment-resistant cancers, plans to raise $75 million at a $424 million market cap. The company's lead candidate ORIC-101 is an antagonist of the glucocorticoid receptor ((GR)), a hormone receptor that has been associated with therapy resistance across a variety of solid tumors and entered into Phase 1b trials in 2019. ORIC Pharmaceuticals is pricing on 4/23.
Three out of the four